New Therapies Bring Progress Against Multiple Myeloma

The 21st century has seen great strides in treatment for multiple myeloma, a cancer of the bone marrow once considered a death sentence. In fact, thanks to research by Dana-Farber scientists, this blood cancer that took the lives of Geraldine Ferraro and Leonard P. Zakim has become a chronic disease for many patients.

Ken Anderson, MD, and his colleagues have helped transform multiple myeloma into a more manageable illness by shepherding many novel drugs from the laboratory to the patient bedside.

Over a decade ago, median survival in multiple myeloma was just 2 to 3 years. Today, James (Jim) Bond of Cleveland, Ohio, who bicycles across his home state every year to raise money for cancer research, has been living with multiple myeloma for 20 years. Bond credits Dana-Farber’s clinical trials for his longevity.

Multiple myeloma leaders Paul Richardson, Nikhil Munshi, and Ken Anderson (left to right)

Multiple myeloma is estimated to strike 22,350 people in the U.S. in 2013. Although there is still no cure, Dana-Farber researchers have contributed to the following advances.

  • Velcade. In 2003, the FDA approved a drug called bortezomib (Velcade), which today is standard treatment for newly diagnosed myeloma, thanks to research conducted by Anderson, Paul Richardson, MD, and their colleagues at Harvard Medical School and elsewhere.
  • Studying the tumor’s “neighborhood.” Around the time that Velcade was approved, Anderson and his team were also investigating the drug thalidomide (Thalomid) as a treatment for myeloma. They explored the effect of medications not just on the tumor cells but also on those surrounding the tumor, including non-cancerous immune and other cells.
  • Thalidomide, Revlimid and Pomalidomide. Anderson and his team discovered that thalidomide and its close cousin lenalidomide (Revlimid) actively recruit immune cells to fight cancer. Clinical trials led by Richardson and colleagues set the stage for the approval of lenalidomide to treat advanced myeloma in 2006. The most potent immunomodulator studied by both the laboratory and clinical team to date, called pomalidomide (Pomalyst), was approved in February 2013.
  • Combination drugs. Because many genetic mutations drive a single tumor, cancer is often best treated with combinations of therapies. Dana-Farber researchers hope to personalize multiple myeloma treatment by categorizing patients based on the molecular pathways that drive their cancer, and prescribe the appropriate combinations of drugs.
  • Stem cell transplant. This procedure is still a key component of treatment for multiple myeloma. DF/BWCC is a leading provider of stem cell transplantation, which involves giving the patient healthy bone marrow harvested from his or her own stem cells, or sometimes those of a donor.
  • Clinical research. Multiple clinical trials at Dana-Farber are open for multiple myeloma patients in various settings. In particular, Richardson and his colleagues have launched a large trial, in collaboration with other medical centers, to test a combination of the drugs lenalidomide, bortezomib, and dexamethasone. Sophisticated testing of myeloma genetics in each patient (led by Nikhil Munshi, MD ) is an integral part of this trial and will hopefully facilitate a highly tailored approach to treatment in the future.

23 thoughts on “New Therapies Bring Progress Against Multiple Myeloma”

  1. My father was diagnosed with Multiple Myeloma in June 2008 and died in April of 2012. I wish more than anything he was lucky enough to be the example of living 20 years with the disease discussed in the article. Dana Farber gave my father the time he did have and I am lucky it was as long as it was, but this post is difficult to read knowing my father was not fortunate enough to have his time be much longer than the previous survival rates. I have an aunt who was diagnosed shortly after my father passed, though, and her prognosis has been much better.

    • Dear Caitlin,
      We are very sorry to hear of the loss of your father. His experience reminds us that there is more work to be done on the multiple myeloma front. You might benefit from Dana-Farber’s bereavement resources. Best wishes to you and your family.

    • My husband was diagnosed with Mutiple Myeloma in 1996 and he passed away January of 2008 I also which he was lucky enough to be the example of living 20 years.

    • Dea Caitlin:

      I lost my mother in January, 2007 to the disease and I absolutely sympathize with your regrets. My mother was discovered quite late in the process and down in Florida where some doctors and care can be considered suspicious at best. However, I do know that she would be pleased to see such progress being made so that other good, decent people will have a better shot at a productive life than she did. That’s just who she was and I’m sure who your father was. My thoughts are with you.

  2. My husband Robert is a patient at Dana-Farber under Dr Laubach. He has Multiple Myeloma and will be harvesting (autologous) stem cells staring 07/29/2013. Dr Jacob Laubach @ Dana-Farber, Dr Preshant Shankar now @ Newton-Wellesley and Dr Christine Wasilewski @ Portsmouth NH all work together to give my husband the best care he could ever have. I pray to have Robert around for many many more years.
    Cecile Poliquin

  3. My wife was diagnosed with asymptomatic MM in 2006. Various medicines have kept it under control. Right now she is on Pomalyst and Dex and is having bad side effects from the Pom-mainly constipation and severe stomach ache. Has anyone else had such a reaction to Pomalyst? Where did you go from there?

  4. Dr Munshi and his colleagues are and always be in my heart for the care concern and love they all showed my husband David during his four year battle with multiple myeloma. I know that what they learned from David will save someone’s life in the future. Bless you all for what you do every day! Susan

  5. My Husband Chuck was diagnosed Feb 2012 with stage 3 Multiple Myeloma, he passed September 2012. It is my hope that something helps others to survive this deadly disease. Revlimid and the other conventional chemotherapy did not help my husband. He was only 57 years old.

    • Dear Barbara,
      We are very sorry to hear of the loss of your husband at such a young age. In his honor our scientists will continue to push the research forward. You might benefit from Dana-Farber’s bereavement resources. Best wishes to you and your family.

  6. My name is Mike Thorn and I have been Blessed with MM since March 2002 and I’m still going strong. My prayers go out to those that have lost their loved ones and to those families living as the caregivers for current patients battling MM. I am not treated at Dana-Faber, protocol being driven by the Myeloma center in Little Rock Arkansas, but want to thank all of the major MM centers that contribute to the battle against this disease. I was stage 3 Igg Kappa and had a relapse in Oct/2010 and the drugs of Revlimid & Velcade along with Dex have gotten this relapse under control. Velcade has been the most successful drug for me.

    So thanks DF for your continued battle against this Cancer.

    rgs Mike

  7. My Mom, age 74, was diagnosed in May of 2006 and lost her life in Jan of 2007. MM was very painful not only in the growth of the tumors but the treatment. She was treated with Thalidomide and Dexadron and radiation. The side effects were depilating. I thank God that HE limited her time of suffering and carried her the rest of the way. I have 2 brothers and always wonder if this is a cancer we should be concerned about in our health.

    I appreciate your constant research and never ending determination in the cure and treatment of this awful disease.

  8. I was diagnosed with MM in August, 2012. It’s essentially one year later and I have gone through 8 cycles of RVD and an auto-stem cell transplant @ the Brigham. My strength, stamina are coming back…and I will be participating in a trial at DFCI. I am optimistic and encouraged by all the good work done by Dr. Richardson and the rest of the international MM research community! I’m 62 now and looking forward to 2-3 more decades of quality life. Congratulations, Dr. Richardson and team on the great progress you have made; I hope my personal participation in trials and donations to DFCI can contribute to further success.

  9. I’m a patient of Dr. Richardson’s and I want to thank him, his team, and all the others in the MM group at Dana Farber. I think they are the best: always caring, professional, and pushing the limits of knowledge about this disease. These are the people who get the research results to real patients as soon as possible, and listen carefully to those patients so they can feed back information to the research people. Again, thank you for all you are doing!

Comments are closed.